Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases

被引:1
|
作者
Liu, Xinyuan [1 ]
Xue, Huiwen [2 ,3 ]
Wirdefeldt, Karin [4 ]
Song, Huan [5 ]
Smedby, Karin [6 ]
Fang, Fang [7 ]
Liu, Qianwei [2 ,3 ]
机构
[1] Fudan Univ, Sch Life Sci, Ctr Evolutionary Biol, Ctr Intelligent Med Res,Greater Bay Area Inst Prec, Guangzhou, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[3] Clin Med Res Ctr Hematol Dis Guangdong Prov, Guangzhou, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat & Clin Neurosci, Stockholm, Sweden
[5] Sichuan Univ, West China Hosp, West China Biomed Big Data Ctr, Chengdu, Peoples R China
[6] Karolinska Inst, Karolinska Univ Hosp, Dept Hematol, Div Clin Epidemiol,Dept Med Solna, Stockholm, Sweden
[7] Karolinska Inst, Inst Environm Med, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
amyotrophic lateral sclerosis; clonal hematopoiesis of indeterminate potential; cohort study; neurodegenerative diseases;
D O I
10.1111/joim.20001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundLittle is known regarding the association between clonal hematopoiesis of indeterminate potential (CHIP) and risk of neurodegenerative diseases.ObjectiveTo estimate the risk of neurodegenerative diseases among individuals with CHIP.MethodsWe conducted a community-based cohort study based on UK Biobank and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of any neurodegenerative disease, subtypes of neurodegenerative diseases (including primary neurodegenerative diseases, vascular neurodegenerative diseases, and other neurodegenerative diseases), and specific diagnoses of neurodegenerative diseases (i.e., amyotrophic lateral sclerosis [ALS], Alzheimer's disease [AD], and Parkinson's disease [PD]) associated with CHIP.ResultsWe identified 14,440 individuals with CHIP and 450,907 individuals without CHIP. Individuals with CHIP had an increased risk of any neurodegenerative disease (HR 1.10, 95% CI: 1.01-1.19). We also observed a statistically significantly increased risk for vascular neurodegenerative diseases (HR 1.31, 95% CI 1.05-1.63) and ALS (HR 1.50, 95% CI 1.05-2.15). An increased risk was also noted for other neurodegenerative diseases (HR 1.13, 95% CI 0.97-1.32), although not statistically significant. Null association was noted for primary neurodegenerative diseases (HR 1.06, 95% CI 0.96-1.17), AD (HR 1.04, 95% CI 0.88-1.23), and PD (HR 1.02, 95% CI 0.86-1.21). The risk increase in any neurodegenerative disease was mainly observed for DNMT3A-mutant CHIP, ASXL1-mutant CHIP, or SRSF2-mutant CHIP.ConclusionIndividuals with CHIP were at an increased risk of neurodegenerative diseases, primarily vascular neurodegenerative diseases and ALS, but potentially also other neurodegenerative diseases. These findings suggest potential shared mechanisms between CHIP and neurodegenerative diseases. image
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [41] CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN PERIPHERAL ARTERY DISEASE
    Buettner, P.
    Boettner, J.
    Krohn, K.
    Baber, R.
    Platzbecker, U.
    Cross, M.
    Thiele, H.
    Branzan, D.
    ATHEROSCLEROSIS, 2022, 355 : E33 - E34
  • [42] Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to atherlosclerotic cardio/cerebro-vascular diseases?
    Li, Fei
    Wu, Xiaojing
    Zhou, Qi
    Zhu, Dennis Weixi
    GENES & DISEASES, 2018, 5 (02) : 75 - 76
  • [43] Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study
    Sun, Ying
    Yu, Yuefeng
    Cai, Lingli
    Yu, Bowei
    Xiao, Wenying
    Tan, Xiao
    Wang, Yu
    Lu, Yingli
    Wang, Ningjian
    CARDIOVASCULAR DIABETOLOGY, 2025, 24 (01)
  • [44] Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia
    Burns, Sarah S.
    Kapur, Reuben
    STEM CELL REPORTS, 2020, 15 (02): : 279 - 291
  • [45] CHIP (Clonal Hematopoiesis of Indeterminate Potential): Potent and Newly Recognized Contributor to Cardiovascular Risk
    Libby, Peter
    Ebert, Benjamin L.
    CIRCULATION, 2018, 138 (07) : 666 - 668
  • [46] Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
    Naqvi, Kiran
    Bravo, Guillermo Montalban
    Pierola, Ana Alfonso
    Yilmaz, Musa
    Sasaki, Koji
    Short, Nicholas J.
    Assi, Rita
    Jabbour, Elias J.
    Ravandi, Farhad
    Benton, Christopher B.
    Kadia, Tapan
    Pierce, Sherry
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Takahashi, Koichi
    Jain, Nitin
    Pemmaraju, Naveen
    Gonzalez, Graciela Nogueras
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2017, 130
  • [47] Association of clonal hematopoiesis of indeterminate potential with increased risk of acute respiratory distress syndrome
    Bae, Eunhye
    Yoon, Jung-Ki
    Kim, Su-Gyeong
    Park, Jimyung
    Cho, Jaeyoung
    Kwak, Nakwon
    Choi, Sun Mi
    Lee, Jinwoo
    Park, Young Sik
    Lee, Chang-Hoon
    Yoo, Chul-Gyu
    Lee, Sang-Min
    RESPIROLOGY, 2023, 28 : 83 - 83
  • [48] Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
    Murphy, Andrew J.
    Dragoljevic, Dragana
    Natarajan, Pradeep
    Wang, Nan
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (09) : 1435 - 1442
  • [49] Potential Protective Roles of Clonal Hematopoiesis of Indeterminate Potential in Angina Pectoris
    Zheng, Yidan
    Zhou, Zihao
    Qian, Xingyu
    Hu, Shiyan
    Xu Jingyu
    Liu, Yuqi
    Tong, Fuqiang
    Li, Fei
    CIRCULATION, 2024, 150
  • [50] Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity
    Feldkamp, Jasper David
    Vetter, Valentin Max
    Arends, Christopher Maximilian
    Lang, Tonio Johannes Lukas
    Bullinger, Lars
    Damm, Frederik
    Demuth, Ilja
    Frick, Mareike
    HAEMATOLOGICA, 2022, 107 (07) : 1703 - 1708